Breaking News Instant updates and real-time market news.

NFLX

Netflix

$348.88

-2.26 (-0.64%)

, JNJ

Johnson & Johnson

$136.53

0.53 (0.39%)

09:03
04/16/19
04/16
09:03
04/16/19
09:03

Fly Intel: Pre-market Movers

HIGHER: Netflix (NFLX), up 1.5% after Deutsche Bank analyst Bryan Kraft upgraded the stock to Buy from Hold and raised his price target for the shares to $400 from $360. Consensus subscriber expectations for both 2019 and 2020 now seem conservative, Kraft tells investors. Netflix is scheduled to report earnings after the closing bell tonight... Crispr Therapeutics (CRSP), up 4% after announcing that the FDA has granted fast track designation to CTX001 for the treatment of transfusion-dependent beta thalassemia... Western Digital (WDC), up 2% after being upgraded to Buy from Hold at Deutsche Bank. UP AFTER EARNINGS: Johnson & Johnson (JNJ), up 1%... UnitedHealth (UNH), up 3%. DOWN AFTER EARNINGS: J.B. Hunt (JBHT), down 4%. ALSO LOWER: JBG Smith Properties (JBGS), down 2% after a 10M share spot secondary priced at $42 per share... Bristow Group (BRS), down 37% after after delaying debt interest payment and announcing strategic review... Wave Life Sciences (WVE), down 13% after presenting final results from Phase 1 suvodirsen study at a Muscular Dystrophy Association meeting.

NFLX

Netflix

$348.88

-2.26 (-0.64%)

JNJ

Johnson & Johnson

$136.53

0.53 (0.39%)

UNH

UnitedHealth

$230.41

7.24 (3.24%)

CRSP

Crispr Therapeutics

$36.98

-0.92 (-2.43%)

WDC

Western Digital

$51.86

0.04 (0.08%)

JBHT

J.B. Hunt

$105.51

-1.15 (-1.08%)

JBGS

JBG Smith Properties

$42.89

-0.25 (-0.58%)

BRS

Bristow Group

$1.07

-0.08 (-6.96%)

WVE

Wave Life Sciences

$34.05

-0.02 (-0.06%)

  • 16

    Apr

  • 16

    Apr

  • 16

    Apr

  • 16

    Apr

  • 16

    Apr

  • 18

    Apr

  • 25

    Apr

  • 29

    Apr

  • 02

    May

  • 14

    May

  • 29

    May

  • 13

    Nov

  • 16

    Apr

NFLX Netflix
$348.88

-2.26 (-0.64%)

04/16/19
BMOC
04/16/19
NO CHANGE
Target $470
BMOC
Outperform
Netflix price target raised to $470 from $440 at BMO Capital
BMO Capital analyst Daniel Salmon raised his price target on Netflix (NFLX) to $470 and kept his Outperform rating ahead of its Q1 earnings today, saying he expects "strong results" from the company. The analyst bases his price target change on his rolled out estimates for 2021-2028 and believes that Netflix still has "room to grow" internationally - particularly in India and Japan - while improving its per subscriber leverage on content spend and generating "steady growth of its consumer product licensing revenues." Salmon also believes that while Netflix remains the clear leader in global streaming, Amazon (AMZN) and Disney (DIS) can also be "long-term winners" in the sector.
04/16/19
DBAB
04/16/19
UPGRADE
Target $400
DBAB
Buy
Deutsche Bank upgrades Netflix to Buy, sees $400 stock in 12 months
Deutsche Bank analyst Bryan Kraft upgraded Netflix to Buy from Hold and raised his price target for the shares to $400 from $360. The streaming service, which reports Q1 results after the bell tonight, closed yesterday down $2.27 to $348.87. Consensus subscriber expectations for both 2019 and 2020 now seem conservative, Kraft tells investors in a research note. Further, Netflix shares have "de-rated enough," which makes the risk/reward profile attractive, adds the analyst. He sees the company's growth in revenue taking the stock to $400 over the next 12 months as the valuation shifts from 2019 to 2020 estimates. Netflix is winning the battle for talent and "looking more and more like a platform every day, rather than just an application," according to Kraft.
04/16/19
DBAB
04/16/19
UPGRADE
DBAB
Buy
Netflix upgraded to Buy from Hold at Deutsche Bank
Deutsche Bank analyst Bryan Kraft upgraded Netflix to Buy from Hold ahead of tonight's Q1 results.
04/16/19
JPMS
04/16/19
NO CHANGE
JPMS
Overweight
Netflix Q1 earnings bar likely lowered amid Disney fears, says JPMorgan
Netflix (NFLX) shares are down 5% since the Disney (DIS) streaming service reveal last week, JPMorgan analyst Doug Anmuth tells investors in a research note. This likely reflects a potential overhang from not being able to disprove the Disney risk until late 2019/early 2020, Disney's initial $6.99 per month price point and "strong enthusiasm" on Disney's content and management's tone around being "all in" on streaming, says Anmuth. The analyst expects Disney+ will likely be the most competitive streaming offering to Netflix, but he does not view it as a major threat to Netflix subscriber numbers given the company's "quality and quantity" of content. Further, given the "strong global secular shift" toward streaming, there is room for multiple companies to succeed, he contends. Anmuth continues to like Netflix shares into tonight's results as he believes the competitive fears will prove overdone. Netflix's first half of 2019 content slate is strong and performing well, and the Q1 earnings bar has likely come down over the past few days, says Anmuth. He keeps an Overweight rating on Netflix shares.
JNJ Johnson & Johnson
$136.53

0.53 (0.39%)

04/05/19
PIPR
04/05/19
NO CHANGE
Target $325
PIPR
Overweight
Piper a 'little cautious' on Q2 results for Cooper Companies
After speaking with a contact lens distributor, Piper Jaffray analyst Matt O'Brien is a "little cautious" on Cooper Companies' fiscal Q2 results. The shift to dailies continues, which is positive for the market as a whole, but Johnson & Johnson (JNJ) and Alcon were more aggressive in calendar Q1, so results for the category "may be a bit unusual," O'Brien tells investors in a research note. In addition to the "odd activity" from the two largest players, the analyst also heard about some "aggressive behavior" from Cooper in recent weeks, which makes him think the company should hit its numbers. He's still bullish on Cooper Companies capturing share in lenses in 2019 and 2020 and keeps an Overweight rating on the name.
04/08/19
PIPR
04/08/19
NO CHANGE
Target $20
PIPR
Overweight
Immunomedics deal with J&J indicates sacituzumab re-filing, says Piper Jaffray
Immunomedics (IMMU) this morning announced that it has entered into an agreement with Johnson & Johnson (JNJ) to provide detailing services to J&J for erdafitinib in the U.S. through Q1 of 2020, Piper Jaffray analyst Joseph Catanzaro tells investors in a research note. The analyst believes the deal will provide incremental revenue to Immunomedics while allowing the company to keep its sacituzumab-trained sales team on board while offsetting some of the costs. Further, the Q1 of 2020 termination suggests a potential timeline for a sacituzumab re-filing and approval, says Catanzaro, who notes Immunomedics has not yet provided guidance. The analyst remains comfortable with his mid-2020 approval timing for sacituzumab and keeps an Overweight rating on Immunomedics with a $20 price target.
04/09/19
NEED
04/09/19
UPGRADE
Target $3
NEED
Buy
Geron upgraded to Buy from Hold at Needham
Needham analyst Chad Messer upgraded Geron (GERN) to Buy with a price target of $3, saying the return of development rights for imetelstat in September by Janssen (JNJ) has created a "buying opportunity". The analyst cites the program's subsequent readouts from Phase II IMbark and IMerge studies in myelofibrosis and myelodysplastic syndrome, which he states has "established efficacy in both patient populations." Messer further contends that big pharma passing on imetelstat does not reflect a fundamental issue with the drug itself.
04/09/19
PIPR
04/09/19
NO CHANGE
Target $32
PIPR
Neutral
Alkermes' ALPINE data an incremental positive, says Piper Jaffray
After Alkermes (ALKS) reported this morning that its ALPINE trial met its primary endpoint and that Aristada showed similar efficacy to the current market leader, Invega Sustenna, at all time points assessed, Piper Jaffray analyst Danielle Brill said she views the data as an incremental positive. However, she thinks it will be challenging to capture share from Johnson & Johnson (JNJ), telling investors that she is "not sure these data will be enough to move the needle." Brill maintains a Neutral rating on Alkermes.
UNH UnitedHealth
$230.41

7.24 (3.24%)

04/10/19
CANT
04/10/19
NO CHANGE
CANT
Senate hearing a net positive for PBMs, says Cantor Fitzgerald
Cantor Fitzgerald analyst Steven Halper views yesterday's Senate hearing as a net positive for the pharmacy benefit managers. The PBMs represented were Cigna (CI), CVS Health (CVS), UnitedHealth (UNH), Humana (HUM) and Prime Therapeutics. Although the Senators were not supportive of the PBMs, the executives responded well to questions and put forth a solid effort to address concerns regarding their business model and incentives, Halper tells investors in a research note. Overall, he views the hearing as a net positive for PBMs "as the group was able to counter the negative sentiment with constructive responses, recognizing this story is far from over."
04/02/19
JEFF
04/02/19
UPGRADE
Target $107
JEFF
Buy
Quest, LabCorp upgraded to Buy ahead of UnitedHealth lab network rollout
Jefferies analyst Brian Tanquilut upgraded both Quest Diagnostics (DGX) and Laboratory Corp. of America (LH) to Buy from Hold on the belief that UnitedHealth's (UNH) rollout on July 1 of its preferred lab network will be a positive catalyst for both stocks. Quest and LabCorp's likely inclusion should bolster their organic growth beginning in 2020, Tanquilut tells investors in a research note. The analyst finds both stocks "compelling" with their 2019 outlooks "seemingly de-risked with fairly conservative guidance ranges" and 2020 consensus estimates "looking conservative." Further, Quest's and LabCorp's valuations are at below-historical relative averages, Tanquilut contends. The analyst raised his price target for Laboratory Corp. to $190 from $154 and for Quest to $107 from $93.
04/01/19
PIPR
04/01/19
NO CHANGE
PIPR
Overweight
Myriad traded lower on 'minor' United Healthcare change, says Piper Jaffray
Shares of Myriad Genetics closed Friday down 4% after United Healthcare (UNH) added a Current Procedural Terminology code and simplified the coverage rationale on its existing medical policy for pharmacogenetics, Piper Jaffray analyst William Quirk tells investors in a research note. The updated policy does not include a review of the Genesight dossier/Guided study, says the analyst. He views the change at United Healthcare as "minor" and keeps an Overweight rating on Myriad Genetics. Quirk continues to look for positive Genesight coverage.
03/21/19
RAJA
03/21/19
UPGRADE
Target $8
RAJA
Outperform
Raymond James upgrades Diplomat Pharmacy, sees number of potential suitors
Raymond James analyst John Ransom upgraded Diplomat Pharmacy (DPLO) to Outperform from Market Perform with an $8 price target. The stock closed yesterday up 14c to $5.86. Following the 56% share decline since the February earnings delay, Diplomat would represent value to a strategic buyer, Ransom tells investor in a research note. The analyst sees a number of potential buyers that would "covet" Diplomat Pharmacy's infusion franchise and could fold its large mail order business into an existing platform, including UnitedHealth (UNH), Cigna (CI), CVS Health (CVS), Anthem (ANTM) and Centene (CNC). Ransom thinks Diplomat's current fundamentals should motivate its board to step up its assessment of strategic options. He believes the company's collection of assets are underappreciated at current valuation levels.
CRSP Crispr Therapeutics
$36.98

-0.92 (-2.43%)

04/02/19
PIPR
04/02/19
NO CHANGE
PIPR
Piper Jaffray says Crispr Therapeutics remains a top pick for 2019
Piper Jaffray analyst Edward Tenthoff reiterated an Overweight rating and $75 price target on Crispr Therapeutics, and added that Crispr remains a top pick for 2019, after the company announced the expansion of its wholly-owned allogeneic CAR-T pipeline at the American Association for Cancer Reseach, or AACR. Tenthoff said he expects more preclinical CAR-T data at the American Society of Gene and Cell Therapy, or ASGCT, in April. The analyst believes the biggest driver for the company remains "first-in-man Phase I/II CTX001 data in Beta-thal and potentially Sickle Cell Disease" this year.
04/11/19
EVER
04/11/19
INITIATION
Target $46
EVER
Outperform
Crispr Therapeutics initiated with an Outperform at Evercore ISI
Evercore ISI analyst Ravi Mehrotra initiated Crispr Therapeutics with an Outperform rating and a price targets of $46. The analyst says the company's ex vivo gene therapy gives it a low risk path to market while it continues to refine its delivery systems required for in vivo editing. Mehrotra also cites Crispr's potential to have several programs in clinic in 2019-2020, along with strong partnerships and clinical execution that "could lead to significant near term clinical news flow."
03/14/19
WBLR
03/14/19
INITIATION
WBLR
Market Perform
William Blair starts Crispr Therapeutics with Market Perform, $39 fair value
William Blair analyst Raju Prasad last night initiated coverage of Crispr Therapeutics with a Market Perform rating and $39 fair value estimate. The analyst acknowledges the innovative nature of the CRISPR/Cas9 discovery but views the most-progressed indications, targeted-beta-thalassemia and sickle cell with CTX001 and allogeneic T-cell therapy for hematological malignancies, as "hyper-competitive spaces where the company is behind the leaders in clinical development." As such, Crispr Therapeutics' current valuation adequately reflects the stage of clinical development for its product candidates, Prasad tells investors in a research note.
03/13/19
WBLR
03/13/19
INITIATION
WBLR
Market Perform
Crispr Therapeutics initiated with a Market Perform at William Blair
William Blair analyst Raju Prasad started Crispr Therapeutics with a Market Perform rating. The analyst views the company as the best pure-play on CRISPR technology, but cites competition and gene editing volatility for his neutral rating.
WDC Western Digital
$51.86

0.04 (0.08%)

04/15/19
DBAB
04/15/19
UPGRADE
DBAB
Buy
Western Digital upgraded to Buy from Hold at Deutsche Bank
04/15/19
04/15/19
UPGRADE

Fly Intel: Top five analyst upgrades
Catch up on today's top five analyst upgrades with this list compiled by The Fly: 1. Disney (DIS) upgraded to Neutral from Sell at BTIG with analyst Richard Greenfield saying the rating change was prompted more by the commentary from CEO Bob Iger on CNBC than by the company's investor day presentation unveiling Disney+. 2. Western Digital (WDC) upgraded to Buy from Neutral at Longbow with analyst Nikolay Todorov saying NAND fundamentals are bottoming and "there is a line of sight to cyclical recovery." 3. Dow Inc. (DOW), Huntsman (HUN), LyondellBasell (LYB), and Eastman Chemical (EMN) upgraded to Buy from Neutral at Nomura Instinet, while Olin (OLN) and Westlake Chemical (WLK) were upgraded to Neutral from Reduce. 4. Waste Management (WM) upgraded to Buy from Hold at Stifel with analyst Michael Hoffman saying even with potential divestitures to get the deal approved, adding Advanced Disposal "dramatically lowers" Waste Management's cost of capital, reduces capital spending, converts more of the fleet to CNG, and stimulates tuck-in activity that should all drive sustainable free cash flow growth. 5. Sony (SNE) upgraded to Buy from Hold at Jefferies. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.
04/15/19
LBOW
04/15/19
UPGRADE
Target $65
LBOW
Buy
Longbow upgrades Western Digital with NAND recovery in 'line of sight'
Longbow Research analyst Nikolay Todorov upgraded Western Digital to Buy from Neutral with a $65 price target. The stock closed Friday up $1.00 to $51.83. NAND fundamentals are bottoming and "there is a line of sight to cyclical recovery," Todorov tells investors in a research note. The analyst believes NAND production is likely to be further rationalized with industry profitability under pressure and points out that pricing has recently shown signs of stabilization. Further, a hard drive revenue and gross margin recovery in the second half of 2019 does not appear to be fully contemplated by the Street, says Todorov. He sees an "asymmetric risk/reward" for Western Digital shares at current levels.
04/15/19
LBOW
04/15/19
UPGRADE
LBOW
Buy
Western Digital upgraded to Buy from Neutral at Longbow
JBHT J.B. Hunt
$105.51

-1.15 (-1.08%)

01/15/19
FBCO
01/15/19
NO CHANGE
Target $121
FBCO
Outperform
J.B. Hunt price target lowered to $121 from $148 at Credit Suisse
Credit Suisse analyst Allison Landry lowered her price target for J.B. Hunt to $121 from $148 due to a higher base year EBIT and a higher discount rate in her DCF model. The analyst reiterates an Outperform rating on the shares.
12/04/18
UBSW
12/04/18
NO CHANGE
Target $124
UBSW
Buy
J.B. Hunt price target lowered to $124 from $145 at UBS
UBS analyst Thomas Wadewitz lowered his price target on J.B. Hunt to $124 from $145 based on falling truckload spot rates in Q3 and what he views as muted/later peak season tightening in the truckload market, which points to incremental addition of capacity. He also sees risk to freight demand from tariffs, cyclical slowing of housing, and risk to energy activity from lower oil prices. Wadewitz maintained his Buy rating on J.B. Hunt shares.
04/16/19
SPHN
04/16/19
NO CHANGE
Target $116
SPHN
Overweight
J.B. Hunt still best positioned in group for long-term growth, says Stephens
After J.B. Hunt missed both top and bottom line expectations in Q1, Stephens analyst Brad Delco attributed the miss to transient events including harsh winter weather, rail line closures and softer than expected demand. While he expects softer intermodal demand to continue in the near-term, Delco sees J.B. Hunt as best positioned in the group for long-term growth with competitive advantages in its markets and keeps an Overweight rating on the shares, though he trimmed his price target to $116 from $118.
04/16/19
BMOC
04/16/19
NO CHANGE
Target $106
BMOC
Market Perform
J.B. Hunt price target lowered to $106 from $110 at BMO Capital
BMO Capital analyst Fadi Chamoun lowered his price target on J.B. Hunt to $106 after its Q1 earnings miss, saying the results highlighted a "decelerating demand environment, increasing competitive conditions, and moderating pricing environment across all segments." The analyst also lowers his FY19 EPS outlook to $5.72 from $6.04 after the Q1 print but believes that the company's operating margins should "improve from recent lows" thanks to the "strong cyclical tailwinds affecting volumes and pricing." Chamoun keeps his Market Perform rating on J.B. Hunt, noting that its valuation looks "balanced at current levels", but adds that he would consider a more constructive stance on a pullback..
JBGS JBG Smith Properties
$42.89

-0.25 (-0.58%)

10/22/18
STFL
10/22/18
UPGRADE
Target $37
STFL
Hold
JBG Smith Properties upgraded to Hold from Sell at Stifel
Stifel analyst John Guinee upgraded JBG Smith Properties (JBGS) to Hold and raised his price target to $37 from $34. The analyst states that some positive news for the REIT could come from Apple (AAPL) as it considers a 20K employee presence at the Center of Innovative Technology near Dulles Airport in Washington DC and also from Amazon (AMZN) as it looks for an urban center expansion. Guinee also says the company stands to benefit from the general growth in cyber security industry and from the "resurgence of the Blue and Yellow Line METRO centric office and multifamily markets".
06/21/18
06/21/18
INITIATION

On The Fly: Top five analyst initiations
Catch up on today's top five analyst initiations with this list compiled by The Fly: 1. Alcoa (AA) initiated with a Neutral at B. Riley FBR while Century Aluminum (CENX) was initiated with a Buy. 2. Westlake Chemical (WLK) initiated with an Outperform at Bernstein while Westlake Chemical Partners (WLKP) was initiated with a Market Perform. 3. RealPage (RP) initiated with an Overweight at JPMorgan. 4. JBG Smith Properties (JBGS) initiated with a Sell at Stifel. 5. Kimberly-Clark (KMB) initiated with an Underweight at Morgan Stanley. This list is just a portion of The Fly's analyst coverage. To see The Fly's full Street Research coverage, click here.
06/21/18
STFL
06/21/18
INITIATION
Target $34
STFL
Sell
JBG Smith Properties initiated with a Sell at Stifel
Stifel analyst John Guinee initiated coverage of JBG Smith (JBGS) with a Sell rating and a $34 target price, stating that it is selling down a relatively old core office portfolio in "one of the worst major office markets in the country" and questioning whether the built-in office portfolio value erosion and land carry can be offset by value creating development and asset re-cycling. Regarding Amazon's (AMZN) HQ2, Guinee said that a decision not to locate in Arlington, Virginia could cause a 5%-15% selloff in JBG Smith shares.
BRS Bristow Group
$1.07

-0.08 (-6.96%)

WVE Wave Life Sciences
$34.05

-0.02 (-0.06%)

08/07/18
STFL
08/07/18
INITIATION
Target $56
STFL
Buy
Wave Life Sciences initiated with a Buy at Stifel
Stifel analyst Paul Matteis initiated Wave Life Sciences (WVE) with a Buy rating and $56 price target, stating that he sees Takeda's (TKPYY) $170M upfront payment as validating to its platform and set of CNS candidates. Wave is one of his favorite names ahead of a catalyst-rich 12-18 months that includes proof-of-concept data in Huntington's in the first half of 2019, and safety and efficacy data for Wave's candidate in Duchenne, Matteis tells investors.
11/27/18
LEER
11/27/18
INITIATION
Target $61
LEER
Outperform
Wave Life Sciences initiated with an Outperform at Leerink
Leerink analyst Mani Foroohar initiated Wave Life Sciences with an Outperform rating and a price target of $61.
11/27/18
LEER
11/27/18
INITIATION
LEER
Leerink initiates select Genetic Medicine names on increasing regulatory clarity
Leerink analyst Mani Foroohar initiated select Genetic Medicine stocks, stating that the field is "is rich with companies developing drugs" to treat rare diseases and that he is increasingly more bullish on "innovation velocity and increasing regulatory clarity in the sector. Based on his "balanced view of pricing dynamics", the analyst issues an Outperform rating on Wave Life Sciences (WVE), Rocket Pharmaceuticals (RCKT), Intellia Therapeutics (NTLA), Eidos Therapeutics (EIDX), Dicerna (DRNA) and Bluebird Bio (BLUE). The analyst likes Wave Life Sciences as a pure play on Oligotherapeutics and its stereopure chemistry platform as a differentiated approach to oligo drug design. Foroohar is positive on Rocket Pharma's lead assets in gene therapies for Fanconi Anemia and Leukocyte Adhesion Deficiency-I "which will likely be the company's first potential approved product." The analyst is positive on Intellia Therapeutics' "robust balance sheet to support development, trading at a material discount to closest comps peers". For Eidos, the analyst cites the prospects of its drug candidate for TTR amyloidosis currently in a placebo-controlled Phase 2 study that may offer a competitive profile relative to Pfizer's (PFE) tafamidis. For Dicerna, Foroohar notes that its DCR-PHXC "is an RNAi therapeutic that targets lactate dehydrogenase A for the treatment of all subtypes of Primary Hyperoxaluria vs. competitor Alnylam's (ALNY) lumasiran, which only treats PH Type 1. For Bluebird Bio, the analyst is positive on its position as a "leader in ex vivo gene therapy, with four programs with visibility towards near-term regulatory approval". Foroohar initiates Avrobio (AVRO), Alnylam (ALNY), and Ionis Pharmaceuticals (IONS) with Market Perform rating based on competitive launches for their products along with "mixed" early signs of their results. The analyst also rates Regenxbio (RGNX) at underperform, saying that its "current valuation more than accounts for robust royalty streams from sales in spinal muscular atrophy" and other partnered assets.
12/06/18
12/06/18
NO CHANGE

Mizuho defending Wave Life Sciences after stock decline
Mizuho analyst Salim Syed maintained a Buy rating and $65 price target on Wave Life Sciences, and defended the stock after its double digit decline. Syed said some of the decline was related to the broader market decline, as the tape is generally red, but some is Wave Life specific, as a lack of details in the company's recent press release has disappointed some investors. The analyst said he spoke to management and believes the decline is unwarranted, as management alleviated concerns regarding the drug trial.

TODAY'S FREE FLY STORIES

NDEKY

Nitto Denko

$0.00

(0.00%)

06:53
04/19/19
04/19
06:53
04/19/19
06:53
Downgrade
Nitto Denko rating change  »

Nitto Denko downgraded to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

CURO

Curo Group

$10.96

0.16 (1.48%)

04:55
04/19/19
04/19
04:55
04/19/19
04:55
Conference/Events
Curo Group management to meet with Jefferies »

Meeting to be held in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 19

    Apr

  • 16

    May

  • 05

    Jun

  • 13

    Nov

04:55
04/19/19
04/19
04:55
04/19/19
04:55
General news
Breaking General news story  »

Week of 4/19 Baker-Hughes…

04:55
04/19/19
04/19
04:55
04/19/19
04:55
General news
Housing Starts Permits to be reported at 08:30 »

March Housing Starts…

04:55
04/19/19
04/19
04:55
04/19/19
04:55
General news
Housing Starts to be reported at 08:30 »

March Housing Starts will…

AON

Aon plc

$175.38

-0.14 (-0.08%)

, MMC

Marsh & McLennan

$93.76

-0.62 (-0.66%)

04:55
04/19/19
04/19
04:55
04/19/19
04:55
Conference/Events
Willis Towers Watson »

Analyst Klauber holds a…

AON

Aon plc

$175.38

-0.14 (-0.08%)

MMC

Marsh & McLennan

$93.76

-0.62 (-0.66%)

WLTW

Willis Towers Watson

$177.37

0.45 (0.25%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 19

    Apr

  • 25

    Apr

  • 26

    Apr

  • 01

    May

  • 07

    May

  • 16

    May

  • 20

    May

  • 11

    Jun

ISRG

Intuitive Surgical

$528.04

3.29 (0.63%)

21:07
04/18/19
04/18
21:07
04/18/19
21:07
Recommendations
Intuitive Surgical analyst commentary at Piper Jaffray »

Intuitive Surgical price…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 18

    Apr

  • 25

    Apr

  • 03

    May

UBER

Uber

$0.00

(0.00%)

, TM

Toyota

$125.10

0.93 (0.75%)

20:35
04/18/19
04/18
20:35
04/18/19
20:35
Hot Stocks
Uber confirms investment from Toyota, DENSO and SoftBank Vision Fund »

Toyota Motor (TM), Denso…

UBER

Uber

$0.00

(0.00%)

TM

Toyota

$125.10

0.93 (0.75%)

DNZOY

Denso

$0.00

(0.00%)

SFTBF

SoftBank

$0.00

(0.00%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 05

    Jun

FIX

Comfort Systems USA

$57.58

0.06 (0.10%)

20:08
04/18/19
04/18
20:08
04/18/19
20:08
Hot Stocks
Comfort Systems USA discloses ransomware attack virus »

The company states:…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 05

    Jun

  • 12

    Jun

  • 13

    Jun

NSANY

Nissan

$0.00

(0.00%)

, RNSDF

Renault

$0.00

(0.00%)

19:29
04/18/19
04/18
19:29
04/18/19
19:29
Periodicals
Nissan to cut global output by 15% in FY19/20, Nikkei reports »

Nissan Motor (NSANY) will…

NSANY

Nissan

$0.00

(0.00%)

RNSDF

Renault

$0.00

(0.00%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

FE

FirstEnergy

$40.51

0.28 (0.70%)

19:13
04/18/19
04/18
19:13
04/18/19
19:13
Hot Stocks
FirstEnergy CEO 'pleased' FES submitted revised disclosure statement »

FirstEnergy Corp.…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 24

    Apr

TSLA

Tesla

$273.25

2.13 (0.79%)

19:03
04/18/19
04/18
19:03
04/18/19
19:03
Periodicals
Tesla CEO, SEC granted one more week to resolve tweet dispute, WSJ says »

Tesla CEO Elon Musk and…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    Apr

  • 24

    Apr

EXPO

Exponent

$56.39

0.23 (0.41%)

, AKRX

Akorn

$2.77

-0.16 (-5.46%)

18:57
04/18/19
04/18
18:57
04/18/19
18:57
Hot Stocks
Fly Intel: After Hours Movers »

UP AFTER EARNINGS:…

EXPO

Exponent

$56.39

0.23 (0.41%)

AKRX

Akorn

$2.77

-0.16 (-5.46%)

ZSAN

Zosano Pharma

$3.41

-0.11 (-3.13%)

FAST

Fastenal

$71.08

0.95 (1.35%)

APHA

Aphria

$7.65

-0.165 (-2.11%)

ISRG

Intuitive Surgical

$528.04

3.29 (0.63%)

PBCT

People's United

$17.12

-0.21 (-1.21%)

I

Intelsat

$19.48

0.235 (1.22%)

LLY

Eli Lilly

$115.20

-1.23 (-1.06%)

PFE

Pfizer

$39.37

-0.5 (-1.25%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 18

    Apr

  • 18

    Apr

  • 18

    Apr

  • 23

    Apr

  • 24

    Apr

  • 25

    Apr

  • 25

    Apr

  • 30

    Apr

  • 30

    Apr

  • 01

    May

  • 01

    May

  • 03

    May

  • 06

    May

  • 07

    May

  • 07

    May

  • 08

    May

  • 09

    May

  • 16

    May

  • 18

    May

  • 05

    Jun

FIVE

Five Below

$141.65

1.82 (1.30%)

18:44
04/18/19
04/18
18:44
04/18/19
18:44
Hot Stocks
Five Below CEO: There is potential for 2,500+ stores in the U.S »

In an interview on…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

LBRT

Liberty Oilfield Services

$16.60

-0.59 (-3.43%)

18:39
04/18/19
04/18
18:39
04/18/19
18:39
Hot Stocks
Liberty Oilfield Services CFO sells 90,000 Class A common shares »

In a regulatory filing,…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Apr

  • 01

    May

  • 22

    May

VNO

Vornado

$67.02

0.77 (1.16%)

18:37
04/18/19
04/18
18:37
04/18/19
18:37
Hot Stocks
Vornado sells 45% equity in flagship NYC assets to institutional investors »

Vornado announced that…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 30

    Apr

  • 16

    May

CHKP

Check Point

$120.01

-9.56 (-7.38%)

18:26
04/18/19
04/18
18:26
04/18/19
18:26
Recommendations
Check Point analyst commentary at Jefferies »

Check Point billings,…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 18

    Apr

CAG

Conagra Brands

$30.53

0.405 (1.34%)

18:11
04/18/19
04/18
18:11
04/18/19
18:11
Hot Stocks
Conagra Brands director Gregor buys 10K shares of common stock »

In a regulatory filing,…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 18

    May

UNP

Union Pacific

$176.70

7.5 (4.43%)

17:52
04/18/19
04/18
17:52
04/18/19
17:52
Periodicals
Union Pacific halts construction of $550M facility in Texas, WSJ reports »

Union Pacific has stopped…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 18

    Apr

  • 16

    May

SO

Southern Company

$51.95

-0.22 (-0.42%)

17:47
04/18/19
04/18
17:47
04/18/19
17:47
Hot Stocks
Southern Company to sell Nacogdoches Generating Facility for $460M »

Southern Power announced…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 01

    May

  • 21

    May

  • 21

    May

TSLA

Tesla

$273.25

2.13 (0.79%)

17:46
04/18/19
04/18
17:46
04/18/19
17:46
Periodicals
Tesla CEO Musk, SEC ask for extension to settle tweet dispute, Reuters says »

Tesla CEO Elon Musk and…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    Apr

  • 24

    Apr

GLD

SPDR Gold Shares

$120.40

0.09 (0.07%)

17:44
04/18/19
04/18
17:44
04/18/19
17:44
Hot Stocks
SPDR Gold Shares holdings fall to 751.68MT from 752.86MT »

This is the lowest level…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

OSW

OneSpaWorld

$13.77

(0.00%)

17:37
04/18/19
04/18
17:37
04/18/19
17:37
Syndicate
Breaking Syndicate news story on OneSpaWorld »

OneSpaWorld files to sell…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

SCHW

Charles Schwab

$45.57

-0.53 (-1.15%)

17:36
04/18/19
04/18
17:36
04/18/19
17:36
Hot Stocks
Charles Schwab EVP Murtagh sells 23.2K shares of common stock »

In a regulatory filing,…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 26

    Apr

  • 15

    May

OSW

OneSpaWorld

$13.77

(0.00%)

17:36
04/18/19
04/18
17:36
04/18/19
17:36
Syndicate
Breaking Syndicate news story on OneSpaWorld »

OneSpaWorld files to sell…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.